AstraZeneca’s biologics division MedImmune is to spin out a new standalone biotech to develop six early-stage inflammation and autoimmunity programmes. To be known as Viela Bio, the spin-out ...
Pharmaceutical Technology on MSN3d
AstraZeneca and Alteogen agree on ALT-B4 platform tech"AstraZeneca and Alteogen agree on ALT-B4 platform tech" was originally created and published by Pharmaceutical Technology, a ...
The Parainfluenza Virus Infection market is expected to surge due to the disease's increasing prevalence and awareness during ...
Alteogen Inc. signed its first billion-dollar partnership this year for ALT-B4 technology through two separate contracts with Astrazeneca plc’s U.K.- and U.S.-based Medimmune subsidiaries worth up to ...
MedImmune, the global biologics R&D arm of AstraZeneca, has acquired Spirogen in a deal worth up to US $440 million. Spirogen is a privately-held biotech focused on antibody-drug conjugate ...
The shift towards new cell culture–based flu vaccine production has been dealt a blow as MedImmune of Gaithersburg, Maryland, puts its manufacturing efforts on hold. The AstraZeneca subsidiary ...
Palivizumab (Synagis; MedImmune/Abbott) is a humanized murine monoclonal antibody against the RSV fusion protein that prevents the spread of virus to the lower respiratory tract 2. It was approved ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback